Protect yourself against RSV with Pfizer’s ABRYSVO^®

content

A single dose of ABRYSVO can help protect you against highly contagious—and potentially serious—RSV.

disclaimer

RSV=respiratory syncytial virus.

headline

A single dose of ABRYSVO helps protect you against RSV

content

In a clinical study among adults 60+, ABRYSVO reduced the risk of lung infections caused by RSV by 86%.

collection-container

content-container

collection-container-variant

grid

collection-item-type

core-content, core-text

number

86%

headline

effective in preventing RSV with 3 or more symptoms*

disclaimer

*RSV symptoms: coughing, sneezing, mucus, shortness of breath and fast breathing.

number

67%

headline

effective in preventing RSV with 2 or more symptoms*

disclaimer

*RSV symptoms: coughing, sneezing, mucus, shortness of breath and fast breathing.

icon

headline

ABRYSVO studies

content

To study the efficacy of ABRYSVO in adults 60+, nearly 37,000 adults aged 60 and older participated in a clinical trial where 18,574 received ABRYSVO and 18,288 received placebo. ABRYSVO was also studied in adults 18 to 59 with certain conditions and helped protect them against RSV.

icon

headline

ABRYSVO side effects

content

The most common side effects reported in adults 60 and older who received ABRYSVO were tiredness, headache, injection-site pain, and muscle pain.

The most common side effects reported in adults 18-59 who received ABRYSVO were injection site pain, muscle pain, joint pain, nausea, tiredness, and headache.

These are not all of the possible side effects. For a full list, please see the full Prescribing Information.

image